Federica Panebianco

Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital.

Screening tumor types for which a first-line, integrated DNA-RNA NGS strategy provides a valuable advantage for rapid therapeutic decisions demonstrates that integrated DNA-RNA high-throughput NGS enables timely, precise molecular profiling for personalized therapy in solid tumors.